We found that the EULAR/ACR/PRINTO 2016 classification criteria26 proved to be accurate and applicable to patients with sJIA‐SD who develop MAS while receiving IL‐1 pathway–blocking therapy. Here, IL1B is linked to macrophage activation syndrome.